The IMF InfoLine team is here to support you and your loved ones with the most up-to-date information about myeloma
Call the IMF InfoLine at 1.800.452.CURE (toll-free in the U.S. & Canada) or 1.818.487.7455 (worldwide), or email InfoLine@myeloma.org with your questions, or if you wish to discuss the contents of this booklet.
Want answers and don’t want to wait?
Get the answers you need anytime from Myelo® , your 24/7 generative AI assistant that is designed to support you living well with myeloma. Ask Myelo your questions at myeloma.org.
Join the Myeloma Knowledge Platform Visit myprofile.myeloma.org and create your online IMF account to receive the most helpful content recommendations tailored to support your personal myeloma experience.
You are not alone
The International Myeloma Foundation (IMF) is here to help you. We are committed to providing information and support for people with multiple myeloma (which we refer to simply as “myeloma”) and their care partners, friends, and family members. The IMF supports the myeloma community with a broad range of resources available on our website myeloma.org, and through numerous programs and services such as publications, seminars, webinars, workshops, and the IMF InfoLine.
Have questions? We can help
The IMF InfoLine responds to your myeloma-related questions and concerns in a compassionate and caring manner. To receive the most up-to-date information, call 1.818.487.7455 or email InfoLine@myeloma.org, or visit mmsm.link/infoline to schedule a convenient time to talk with an IMF InfoLine Coordinator.
Want answers and don’t want to wait? Ask Myelo®, your 24/7 generative AI assistant at myeloma.org that is designed to support you in your life with myeloma and help you find the right resources.
IMF publications
Myeloma is a cancer that most people have not heard of at the time of their diagnosis. If you have been diagnosed with myeloma or if you suspect that you might have myeloma, the IMF can help you understand this disease so that you can take an active role in your own medical care and make good decisions about your care in partnership with your doctor.
The IMF’s Patient Handbook provides an explanation of myeloma, its diagnosis and risk stratification, its effects on the body, as well as treatment options and supportive care methods. The Patient Handbook will also point you to other helpful resources.
The IMF’s Understanding-series is intended to offer more information about a large range of myeloma-specific topics, including symptoms, treatments, and side effects that may be caused by myeloma or by its treatments.
All IMF publications are free and can be read, downloaded, or requested in printed format at publications.myeloma.org. If you prefer to read IMF publications digitally, just click on the light blue links.
Understanding myeloma vocabulary
Words in bold+blue in IMF publications are explained in a companion booklet, Understanding Myeloma Vocabulary, which you can read or download at glossary.myeloma.org. Myeloma is a complicated disease,
but the language that describes it doesn’t have to be hard to understand. Being comfortable with myeloma-related terms is helpful to understanding the content of these publications and to making your conversations with your doctor more effective.
What you will learn from this booklet
This booklet discusses Darzalex® (also known by its generic drug name, daratumumab) and its newer formulation, Darzalex Faspro® (daratumumab + hyaluronidase-fihj). You will learn how this medication works, its dose and schedule, clinical trial experience with Darzalex and Darzalex Faspro, and the potential side effects for you to discuss with your doctor. You will also learn about support programs for patients who are prescribed this medication.
Who can receive Darzalex and Darzalex Faspro
In 2015, Darzalex became the first monoclonal antibody to be approved by the U.S. Food and Drug Administration (FDA). Darzalex targets the CD38 protein on the surface of myeloma cells. Darzalex is given as an intravenous (IV) infusion into a vein. The dose is determined by the patient’s weight. The first infusion is usually given in a clinic over a period of up to 8 hours.
In 2020, the FDA approved a newer formulation of this medication. Darzalex Faspro is given as a subcutaneous (SQ) injection (shot) under the skin of your abdomen. The injection is given by a healthcare professional at your doctor’s office or in a clinic, and it takes only 3 to 5 minutes. The dose is a fixed amount of medication. Darzalex Faspro does not need to be calculated based on the patient’s weight.
Darzalex and Darzalex Faspro have been shown to be equally effective. But the chances of having a bad reaction to the treatment is lower with Darzalex Faspro. For example, clinical trials have shown that the rate of infusion-related reactions (IRR) is 13% with Darzalex Faspro vs. 34% with Darzalex.
How Darzalex and Darzalex Faspro work
Antibodies, also called immunoglobulins (Ig), are a natural part of the human immune system. Darzalex is a laboratory-made monoclonal antibody designed to function like a natural antibody. Darzalex is called “targeted therapy” because it targets a specific protein on the surface of myeloma cells. It punches holes in the myeloma cells to kill them.
Darzalex targets and binds to the CD38 protein (glycoprotein) on the surface of myeloma cells. “CD” in CD38 stands for “cluster of differentiation,” a system for identifying the various molecules that serve as binding sites. CD38 is found in very high amounts on the surface of myeloma cells in the bone marrow. CD38 is found in very low amounts on healthy cells, making it easier for the healthy cells to recover after treatment.
In brief, Darzalex works in the following ways:
¡ Darzalex kills myeloma cells directly,
¡ Darzalex enlists the cells of the human immune system cells to attach to the Darzalex-CD38 complex and kill the myeloma cells,
¡ Darzalex recruits complement proteins that boost the killing power of antibodies,
¡ Darzalex prevents the cellular transfer of calcium ions, which is toxic to cancer cells but not to normal cells.
For more information about the human immune system, read the IMF’s publication, Understanding the Immune System in Myeloma.
FDA-approved treatment regimens
Regimens with Darzalex IV
Please note that patients who began receiving Darzalex IV can be transitioned by their doctor to receive Darzalex Faspro SQ.
Frontline therapy is the initial treatment given to a patient with newly diagnosed multiple myeloma (NDMM):
¡ Darzalex + Velcade® (bortezomib) + thalidomide + dexamethasone [DVTd] in patients who are eligible for autologous stem cell transplant (ASCT).
¡ Darzalex + Revlimid® (lenalidomide) + dexamethasone [DRd] in patients who are not eligible (ineligible) for ASCT.
¡ Darzalex + Velcade + melphalan + prednisone [DVMP] in patients who are ineligible for ASCT.
For patients with relapsed or refractory multiple myeloma (RRMM):
¡ Darzalex + Revlimid + dexamethasone [DRd] in patients who have received at least 1 prior therapy.
¡ Darzalex + Velcade + dexamethasone [DVd] in patients who have received at least 1 prior therapy.
¡ Darzalex + Kyprolis® (carfilzomib) + dexamethasone [DKd] in patients who have received 1 to 3 prior lines of therapy.
¡ Darzalex + Pomalyst® (pomalidomide) + dexamethasone [DPd] in patients who have received at least 2 prior therapies including Revlimid + a proteasome inhibitor (Velcade, Kyprolis, or Ninlaro® [ixazomib]).
¡ Darzalex as a single agent (monotherapy) in patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor (Velcade, Kyprolis, or Ninlaro) and an immunomodulatory agent (Pomalyst, Revlimid, or thalidomide) or who are double-refractory both to a proteasome inhibitor and to an immunomodulatory agent.
Regimens with Darzalex Faspro SQ
For patients with high-risk (HR) smoldering multiple myeloma (SMM):
¡ Darzalex Faspro monotherapy in adults with HR-SMM.
For patients with newly diagnosed multiple myeloma (NDMM):
¡ Darzalex Faspro + Velcade + Revlimid + dexamethasone [DVRd] as induction therapy and consolidation therapy in patients who are eligible for ASCT.
¡ Darzalex Faspro + Revlimid + dexamethasone [DRd] in patients who are ineligible for ASCT.
¡ Darzalex Faspro + Velcade + thalidomide + dexamethasone [DVTd] in patients who are eligible for ASCT.
¡ Darzalex Faspro + Velcade + melphalan + prednisone [DVMP] in patients who are ineligible for ASCT.
For patients with relapsed or refractory multiple myeloma (RRMM):
¡ Tecvayli® (teclistamab-cqyv) + Darzalex Faspro [ Tec-Dara] in patients who have received at least 1 prior line of therapy.
¡ Darzalex Faspro + Revlimid + dexamethasone [DRd] in patients who have received at least 1 prior therapy.
¡ Darzalex Faspro + Velcade + dexamethasone [DVd] in patients who have received at least 1 prior therapy.
¡ Darzalex Faspro + Pomalyst + dexamethasone [DPd] in patients who have received at least 1 prior line of therapy including Revlimid and a proteasome inhibitor.
¡ Darzalex Faspro + Kyprolis + dexamethasone [DKd] in patients who have received 1 to 3 prior lines of therapy.
¡ Darzalex Faspro monotherapy in patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double-refractory both to a proteasome inhibitor and to an immunomodulatory agent.
Combination therapies
Darzalex IV and Darzalex Faspro SQ are typically used in combination with other drugs. To learn more about these drugs, read the following IMF publications:
¡ Understanding Dexamethasone in the Treatment of Myeloma
¡ Understanding KYPROLIS® (carfilzomib)
¡ Understanding POMALYST® (pomalidomide)
¡ Understanding REVLIMID® (lenalidomide)
¡ Understanding TECVAYLI® (teclistamab-cqyv)
¡ Understanding Thalidomide Therapy
¡ Understanding VELCADE® (bortezomib)
¡ Understanding the VRd Regimen for Newly Diagnosed Myeloma
Clinical trial experience with Darzalex
A clinical trial is a medical research study with people who volunteer to test scientific approaches to a new treatment or a new combination therapy. Each clinical trial is designed to find better ways to prevent, detect, diagnose, or treat a medical condition, or to answer scientific questions.
A clinical trial is launched only after laboratory studies have shown the potential of a treatment or procedure to be more effective and/or less harmful than previous methods. For patients with myeloma, clinical trials can be part of normal care that may provide earlier access to new drugs and therapies that are not yet available outside of a study.
DVRd for ASCT-eligible patients
At the annual meeting of the American Society of Hematology (ASH) in December 2019, data were presented from the GRIFFIN phase II clinical trial. This trial compared VRd vs. DVRd in induction therapy and for 2 Cycles of consolidation therapy after ASCT. This first introduced the idea of adding Darzalex to the VRd combination.
After the GRIFFIN study ended, an analysis of sustained minimal residual disease (MRD) was presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2022. Data showed that DVRd induction therapy and consolidation therapy followed by Revlimid maintenance therapy may lead to durable MRD-negativity in ASCT-eligible patients with NDMM, high-risk cytogenetics, ISS stage III myeloma, and those who achieve complete response (CR) or stringent complete response (sCR).
MRD is the presence of residual cancer cells after treatment has been completed. MRD-negativity means that not even 1 myeloma cell was found in 100,000 or 1,000,000 sampled bone marrow plasma cells (depending on the test being used)!
At the annual meeting of ASH in December 2023, the primary results of the PERSEUS phase III clinical trial showed that DVRd significantly improved progression-free survival (PFS) in ASCT-eligible patients with NDMM and increased depth of response (DpR). PFS is the length of time during and after treatment that a patient lives with myeloma but the disease does not relapse.
These results support the use of DVRd followed by maintenance therapy with Darzalex + Revlimid [D-R] as a new standard of care for ASCT-eligible patients with NDMM when compared to VRd alone followed by maintenance with Revlimid.
Even before the FDA approval, DVRd was included in the National Comprehensive Cancer Network (NCCN) guidelines for the management of myeloma.
DVRd for ASCT-ineligible patients
In 2026, the FDA expanded its approval of DVRd to include patients with NDMM who were ineligible for ASCT or who declined ASCT as frontline therapy. The expanded approval is based on data from the CEPHEUS clinical trial of 395 patients, 197 in the DVRd arm of the study and 198 in the VRd arm (without Darzalex Faspro).
The CEPHEUS study demonstrated significant benefit as measured by MRD-negativity and PFS. MRD-negativity was 52.3% in the DVRd arm vs. 34.8% in the VRd arm. At a follow-up of 54 months, approximately 68% of patients in the DVRd arm remained progression-free vs. approximately 48% in the VRd arm. DVRd demonstrated a 43% lower risk of progression or death vs. VRd. Median PFS was not reached in the DVRd arm of the study, indicating superior, long-lasting, durable responses compared to the VRd arm.
The CEPHEUS study confirmed that for patients who are not proceeding to transplant as frontline therapy, DVRd is a new standard of care (SOC). Standard of care is a benchmark treatment that is widely accepted by medical experts as the most appropriate.
DVRd has become the SOC regimen for the majority of ASCT-eligible patients, as well as for fit or intermediate-fit ASCT-ineligible patients.
Tec-Dara for patients with RRMM
In March 2026, the FDA approved the combination of Tecvayli + Darzalex Faspro [Tec-Dara] for patients with RRMM with at least 1 prior line of therapy. The application for approval was granted priority review by the FDA and was expedited. The FDA approval is based on the efficacy of Tec-Dara evaluated in the MajesTEC-3 clinical trial.
The MajesTEC-3 study added insight into the power of Tec-Dara. The 3-year PFS was over 90% in patients with standard-risk myeloma – a number never seen before – and 80% in patients with high-risk multiple myeloma (HRMM). This study further strengthened the argument for considering Tec-Dara in early relapse of myeloma.
Darzalex Faspro monotherapy for HR-SMM
In November 2025, the FDA granted its first-ever approval of a treatment for adult patients with HR-SMM, based on data from the AQUILA clinical trial. This study of 390 patients compared treatment with Darzalex Faspro for 3 years vs. observation (active monitoring) but no treatment. Darzalex Faspro is approved for patients with HR-SMM. It is not approved for other risk categories of SMM. For more information, read the IMF’s publication Understanding MGUS and Smoldering Multiple Myeloma.
Finding a clinical trial to match your needs
Myeloma clinical research is very exciting, with many studies enrolling patients. To help you with personalized support for identifying clinical trial options across the U.S., the IMF has partnered with SparkCures. Visit myeloma.org/sparkcures or contact the IMF InfoLine for more information.
If you would like to explore possible participation in a clinical trial, ask your myeloma doctor if being part of a study may be right for you. Ask about the potential risks and benefits that may apply to you. For more information about what’s involved in study participation, read the IMF’s publication Understanding Clinical Trials in Myeloma.
Dose and schedule
Darzalex Faspro SQ
Darzalex Faspro SQ can be given on the same schedule as Darzalex IV, but it is administered as an injection into the abdomen that takes only a few minutes. Patients are monitored for a few hours after the first one or two doses.
The recommended dosage of Darzalex Faspro is 1,800 mg Darzalex + 30,000 units hyaluronidase per 15 mL (120 mg and 2,000 units/mL) solution in a single-dose vial. Before receiving an injection, patients are given a steroid, acetaminophen, and a histamine-1 receptor antagonist in order to prevent or minimize possible side effects. Your doctor may also recommend medication after your injection.
Darzalex IV
Very few patients are receiving Darzalex IV after the FDA approved Darzalex Faspro SQ. For patients who are still prescribed Darzalex IV, the first dose of is given over a period of up to 8 hours. As with Darzalex SQ, medications can be given before and after each Darzalex infusion to help prevent IRR.
Splitting the first dose of Darzalex IV over 2 consecutive days is called “splitdosing.” This is approved in the United States and in Europe. Split-dosing is not done with Darzalex Faspro SQ.
The slower the infusion during the first dose, the less likely it is that a patient will experience severe IRR. If you tolerate your first dose well, your next doses may be given more rapidly at your doctor’s discretion.
Special precautions
All myeloma treatments require close monitoring. Both Darzalex IV and Darzalex Faspro SQ have the potential to cause Grade 3 or 4 side effects. A side effect is an unwanted or unexpected effect caused by a drug. In the U.S., the National Cancer Institute (NCI) toxicity is categorized as follows:
• Grade 0 – no symptoms,
• Grade 1 – mild symptoms,
• Grade 2 – moderate symptoms,
• Grade 3 – symptoms requiring treatment,
• Grade 4 – symptoms requiring urgent intervention,
• Grade 5 – symptoms resulting in death.
Hypersensitivity, IRR, and ARR
Hypersensitivity is an undesirable reaction that may occur if a drug overactivates the immune system or the patient has a non-immune activation. Some drug classes, including monoclonal antibodies, are known to cause hypersensitivity reactions. A mild hypersensitivity reaction may be uncomfortable, but a severe reaction may be life-threatening. If you experience a hypersensitivity reaction to Darzalex, your doctor will decide if you should stop receiving it.
An infusion-related reaction (IRR) may occur due to the release of cytokines, proteins that circulate in the bloodstream. This is sometimes called cytokine release syndrome (CRS). Reactions may be flu-like and include nasal congestion, fever, chills, cough, throat irritation, difficulty breathing, low blood pressure, nausea, and rash. In the Darzalex IV registration trials, IRR occurred in 46% of patients. IRR was mostly mild to moderate and decreased with subsequent infusions, but 3% of patients had IRR severe enough to require hospitalization. There were no life-threatening reactions.
To minimize the risk of IRR, patients receive medication before every infusion of Darzalex IV. If dexamethasone is part of the treatment regimen, it may serve as pre-medication on days when Darzalex IV is given. A clinical trial published in 2018 evaluated the use of montelukast 10 mg as a premedication for Darzalex IV. Patients who received montelukast had lower rates of IRR during their first infusion, and the median duration of the first infusion was shorter. In 2022, a retrospective study of montelukast as a pre-medication for Darzalex IV confirmed that the rate of IRR was lower
with montelukast than without it. If a reaction of any kind occurs during the administration of Darzalex IV, the infusion will be stopped.
Systemic administration-related reaction (ARR), a broader term that includes IRR, was documented in approximately 7%–11% of patients receiving Darzalex Faspro SQ in a clinical trial.
Risk of herpes zoster infection
Herpes zoster (“shingles”) is caused by the reactivation of the varicellazoster virus (VZV), the same virus that causes varicella (“chickenpox”). Herpes zoster frequently affects nerves. A small percentage of patients in clinical trials developed shingles.
All patients should receive preventive treatment with antiviral medication within 1 week after starting Darzalex. Patients should continue taking an antiviral medication for 3 months following the last dose of treatment with Darzalex.
Risk of hepatitis B virus reactivation
At any treatment phase, Darzalex IV can cause the reactivation of the hepatitis B virus (HBV). This has been reported in fewer than 1% of clinical trial patients, but there were fatal cases. Regular monitoring is required on a long-term basis. Ask your doctor if prevention strategies are recommended in your particular case.
Neutropenia, lymphopenia, thrombocytopenia
Neutropenia is a reduced level of neutrophils, a type of white blood cell necessary to combat bacterial infection. Lymphopenia (also called lymphocytopenia) is low levels of B cells, T cells, and natural killer (NK) cells.
Thrombocytopenia is a low number of platelets (thrombocytes) in the blood. The “normal” level varies from laboratory to laboratory. For example, at Mayo Clinic the “normal” level is ≥150,000 platelets per microliter of circulating blood. If the platelet count is less than 50,000, bleeding problems may occur. Major bleeding is usually associated with a reduction in count to less than 10,000 platelets.
In studies with Darzalex Faspro SQ, blood tests in 40% or more patients identified decreased leukocytes, decreased platelets, and decreased hemoglobin. Your doctor will use the complete blood count (CBC) test to monitor you during treatment.
If your blood cell counts are low, your doctor will either hold your dose of Darzalex until your counts improve or will provide you with supportive care in the form of transfusions or medications that stimulate the formation of new blood cells.
Embryo-fetal toxicity
Women of reproductive potential and males with female partners of reproductive potential must ask the doctor which effective contraception method to use, and how long to continue using contraception after the last dose of treatment is received. Due to the potential for harm in the breastfed child, lactating women should not breastfeed during treatment and for a period of time after treatment ends.
Interference with blood tests
Darzalex and Darzalex Faspro can interfere with red blood cell (RBC) antibody screening. Darzalex and Darzalex Faspro may also interfere with blood compatibility testing, including the matching done prior to blood transfusions. Before starting Darzalex or Darzalex Faspro, your doctor should screen your blood and establish your blood type in case you might need a blood transfusion later. Blood banks must be informed that you have received Darzalex or Darzalex Faspro.
Darzalex is known to interfere with the results of serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) tests used to monitor myeloma. This can lead to inaccurate results when testing for complete response or disease progression. In 2018, the FDA approved a new blood test for evaluating M-protein in patients treated with Darzalex.
Other possible side effects
Side effects that were reported in 20% or more patients in clinical trials include the following:
Fatigue
In the registration trials for Darzalex, 39% of the patients experienced fatigue, all but 2% of which was mild to moderate and did not limit the patients’ ability to care for themselves. Exercise caution when operating machinery, including automobiles. The effects of fatigue may be minimized by maintaining:
¡ A moderate level of activity.
¡ A healthy diet and sufficient fluid intake.
¡ A consistent sleeping schedule with enough rest.
¡ Regularly scheduled visits with your healthcare team to discuss issues that may contribute to your fatigue.
¡ A careful review of the side effects of any other products you are taking to ensure that they are not contributing to your fatigue.
For more information, please see the IMF publication Understanding Fatigue in Myeloma.
Nausea
Approximately 25% of the patients in the registration trials for Darzalex IV had mild to moderate nausea. There were no cases of severe nausea. Medications given before and after helped reduce the occurrence and severity of nausea. Ask your doctor prior to your Darzalex IV infusion if you need to fill a prescription of anti-nausea in advance.
Back pain
If you have myeloma-related back pain, read the IMF’s publication Understanding Treatment of Myeloma Bone Disease.
If you have treatment-related back pain and body aches, this could be due to the release of cytokines in the bloodstream in reaction to Darzalex. Back pain and body aches may also occur if you develop an infection due to low levels of white blood cells (WBC). In the Darzalex registration trials, 25% of patients experienced back pain, with 2% experiencing back pain that limited their ability to care for themselves. Medications given before and after your dose of Darzalex IV may reduce or prevent infusion-related back pain.
Fever
Fever can be a sign of the interaction of Darzalex with the immune system. To protect yourself, be proactive in the following ways:
¡ Check your temperature twice a day if you feel warm.
¡ If you have an oral temperature greater than 100.4°F (38°C), you must get medical care immediately.
¡ If you are not able to reach your healthcare team, go to an emergency room (ER) or urgent care facility.
¡ To avoid dehydration, drink a lot of non-alcoholic and non-caffeinated liquids.
¡ To control the fever, do not take any medication on your own. Take medication only as directed by a medical professional familiar with your medical history.
If your fever is a result of an infection, you may be prescribed antibiotics. You may also be given a colony-stimulating factor (CSF) to stimulate the development and growth of white blood cells.
Cough
Cough can be managed with medication taken before and after your infusion of Darzalex IV. If you develop a cough as a result of an upper respiratory infection, your doctor will give you medication, if needed. Typically, you help relieve your cough by:
¡ Maintaining good hydration,
¡ Drinking hot or warm liquids,
¡ Taking throat lozenges,
¡ Avoiding irritants,
¡ Breathing warm steam from a shower or humidifier.
Respiratory problems
In the registration trials for Darzalex, 20% of the patients experienced an upper respiratory tract infection; all but 1% were mild to moderate. Upper respiratory tract infections can be a bacterial or viral infection of the nose, throat, sinuses, or larynx. Possible respiratory infections include lung problems such as pneumonia (an infection in one or both lungs). Shortness of breath is also a common side effect.
Immediately report your symptoms to your doctor. If your infection is serious and your white blood cell count is low, the doctor may pause your Darzalex IV until you recover or support you with medications to help with the production of new white blood cells.
Peripheral neuropathy
Peripheral neuropathy (PN) is a serious condition that affects nerves in the hands, feet, lower legs, and/or arms. Myeloma patients may experience PN from the effects of the disease itself or from treatments for myeloma. Symptoms of PN may include a feeling of:
¡ Numbness ¡ Tingling, ¡ Burning, ¡ Pain.
Velcade, a drug that is part of many myeloma combination therapies, including regimens with Darzalex or Darzalex Faspro, is known to cause PN. Velcade causes significantly less PN when it is given as an SQ injection under the skin rather than as an IV infusion. In a clinical trial, 6% of patients who received Velcade SQ experienced PN of Grade 3 or 4 vs. 16% of patients who received Velcade IV. If Velcade IV is part of your regimen, be sure to ask your doctor about Velcade SQ.
Diarrhea
Diarrhea is defined as 3 or more loose stools per day. Severe diarrhea is defined as 7 or more loose stools per day. Dizziness, lightheadedness, or fainting may occur due to dehydration caused by either excessive or persistent diarrhea.
Precautions should be taken to prevent dehydration. Ask your doctor how you can maintain an adequate level of hydration. Contact your doctor if you experience dizziness, lightheadedness, or fainting. Your doctor may administer antidiarrheal medication or intravenous fluids on an outpatient basis or may recommend hospitalization if needed.
Constipation
The medical definition of constipation is 3 or fewer bowel movements in 1 week. The stool may become hard, dry, and difficult to pass. You may experience stomach cramps and bloating. Not eating, not drinking enough water, and being less active can make constipation worse.
Ask your doctor for instructions on drinking sufficient fluids and eating high-fiber foods. Try to be active every day, even if you exercise in a chair. Moving your body increases the rhythmic contractions that move food through your intestines.
Patient assistance
If you are prescribed Darzalex or Darzalex Faspro, you can sign up for the “DARZALEX withMe” program. Visit darzalex.com or call
Monday–Friday, 8 a.m.–8 p.m. (ET) for access to a Care Navigator who can help guide you to support solutions throughout your treatment with Darzalex.
In closing
This booklet is not meant to replace the advice of your doctors and nurses who are best able to answer questions about your specific healthcare management plan. The IMF provides educational information that will guide you in your conversations with your healthcare team.
To help ensure a good quality of life through effective treatment, you must have an active role in your own medical care. Please visit myeloma.org and join the IMF Myeloma Knowledge Platform at myprofile.myeloma.org.
Click on the links included in this booklet for quick access to a variety of resources. Sign up at subscribe.myeloma.org for our quarterly journal Myeloma Today and weekly e-newsletter Myeloma Minute, as well as alerts about IMF news, events, and actions.
Founded in 1990, the International Myeloma Foundation (IMF) is the world’s leading organization dedicated to multiple myeloma. The IMF is steadfast in its mission: Accelerating the prevention and cure of myeloma and improving the quality of life for patients and families.
The IMF serves people impacted by myeloma at every stage of the disease by combining world-class research, trusted education, global advocacy, and direct support. A cornerstone of this work is the International Myeloma Working Group® (IMWG) – a network of more than 300 internationally renowned researchers and clinicians who establish the guidelines that shape how myeloma is diagnosed, treated, and managed across the globe.
Through its global network of support groups, educational programs, its 24/7 generative-AI myeloma assistant Myelo® , its InfoLine staff, and its advocacy for greater healthcare access, the IMF helps people living with myeloma and their care partners navigate diagnosis, treatment, and survivorship. At the same time, the IMF ensures scientific advances translate into better care and outcomes.